Fangda represented IDG as the co-leading investor in the Series C round financing of Hang Zhou Sciwind Biosciences Co., Ltd. (“Sciwind Biosciences”), involving an aggregate transaction price of RMB450 million. This deal was announced on October 12, 2021. Fangda team on this deal was led by partner Wei Chen and Tess Lin, and the team members include Snow Feng, Synne Li and Kristen Sun. Fangda handled the legal due diligence as well as the negotiation and preparation of transaction documents for this deal. Sciwind Biosciences is a bio-technology company dedicated in the development of innovative therapies to treat metabolic disease.